Wenbin Jiang's Insider Trades & SAST Disclosures
Wenbin Jiang's most recent trade in Cytek BioSciences Inc was a trade of 29,467 Restricted Stock Units done . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Wenbin Jiang.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 29,467 | 265,206 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 29,467 | 5,232,909 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 15,708 | 5,208,100 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 15,708 | 94,253 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 7,998 | 5,224,911 | - | 4.4 | 34,871 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 4,658 | 5,203,442 | - | 4.4 | 20,309 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 735,294 | 735,294 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 464,037 | 464,037 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 6,758 | 5,194,396 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 6,758 | 24,788 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.31 per share. | 18 Feb 2025 | 2,004 | 5,192,392 | - | 5.3 | 10,641 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 22,100 | 5,193,020 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 22,100 | 294,673 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 11,781 | 5,173,789 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 11,781 | 109,961 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 6,758 | 31,546 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 6,758 | 5,163,654 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 5,382 | 5,187,638 | - | 6.0 | 32,453 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 2,869 | 5,170,920 | - | 6.0 | 17,300 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 1,646 | 5,162,008 | - | 6.0 | 9,925 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Sep 2024 | 200,000 | 5,156,896 | - | 0 | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 22,100 | 5,362,278 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 22,100 | 316,773 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 11,781 | 121,742 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 11,781 | 5,343,047 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 6,758 | 38,304 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 6,758 | 5,332,912 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 5,382 | 5,356,896 | - | 5.5 | 29,762 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 2,869 | 5,340,178 | - | 5.5 | 15,866 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 1,646 | 5,331,266 | - | 5.5 | 9,102 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 14,733 | 338,873 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 14,733 | 5,329,742 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 7,854 | 133,523 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 7,854 | 5,316,922 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 6,758 | 45,062 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 6,758 | 5,310,669 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.96 per share. | 20 May 2024 | 3,588 | 5,326,154 | - | 6.0 | 21,384 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.96 per share. | 20 May 2024 | 1,913 | 5,315,009 | - | 6.0 | 11,401 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.96 per share. | 20 May 2024 | 1,601 | 5,309,068 | - | 6.0 | 9,542 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 15,708 | 5,308,557 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 15,708 | 141,377 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.22 per share. | 11 Mar 2024 | 4,646 | 5,303,911 | - | 7.2 | 33,544 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 526,315 | 526,315 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 353,606 | 353,606 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Jiang Wenbin | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 6,758 | 5,294,853 | - | - | Common Stock | |
| Cytek BioSciences Inc | Jiang Wenbin | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 6,758 | 51,820 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.38 per share. | 20 Feb 2024 | 2,004 | 5,292,849 | - | 8.4 | 16,794 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 11,781 | 7,629,761 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 11,781 | 168,866 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 6,758 | 65,336 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 6,758 | 7,620,225 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 18 Aug 2023 | 3,965 | 7,625,796 | - | 8.5 | 33,544 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 18 Aug 2023 | 2,245 | 7,617,980 | - | 8.5 | 18,993 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.04 per share. | 07 Aug 2023 | 20,000 | 7,613,467 | - | 9.0 | 180,800 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.23 per share. | 07 Jun 2023 | 20,000 | 7,653,467 | - | 8.2 | 164,600 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 7,854 | 7,676,418 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 7,854 | 180,647 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 6,758 | 7,671,197 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 6,758 | 72,094 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.69 per share. | 18 May 2023 | 2,951 | 7,673,467 | - | 6.7 | 19,742 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.69 per share. | 18 May 2023 | 2,633 | 7,668,564 | - | 6.7 | 17,615 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.55 per share. | 08 May 2023 | 20,000 | 7,664,439 | - | 11.6 | 231,000 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.88 per share. | 10 Apr 2023 | 20,000 | 7,684,439 | - | 8.9 | 177,600 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 284,900 | 284,900 | - | - | Employee Stock Option (Right to Buy) | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 188,501 | 188,501 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.13 per share. | 03 Mar 2023 | 20,000 | 7,704,439 | - | 10.1 | 202,600 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 6,758 | 7,727,072 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 6,758 | 78,852 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.97 per share. | 21 Feb 2023 | 2,633 | 7,724,439 | - | 11.0 | 28,884 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.19 per share. | 07 Feb 2023 | 20,000 | 7,720,314 | - | 13.2 | 263,800 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.66 per share. | 09 Jan 2023 | 20,000 | 7,740,314 | - | 10.7 | 213,200 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.86 per share. | 07 Dec 2022 | 20,000 | 7,760,314 | - | 11.9 | 237,200 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Dec 2022 | 10,000 | 7,780,314 | - | 0 | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2022 | 6,758 | 7,792,578 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2022 | 6,758 | 85,610 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.75 per share. | 18 Nov 2022 | 2,264 | 7,790,314 | - | 14.8 | 33,394 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.76 per share. | 07 Nov 2022 | 20,000 | 7,785,820 | - | 14.8 | 295,200 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.79 per share. | 07 Oct 2022 | 20,000 | 7,805,820 | - | 14.8 | 295,800 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.09 per share. | 08 Aug 2022 | 20,000 | 7,841,541 | - | 15.1 | 301,800 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.19 per share. | 07 Jul 2022 | 20,000 | 7,861,541 | - | 11.2 | 223,800 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.75 per share. | 07 Jun 2022 | 20,000 | 7,881,541 | - | 10.8 | 215,000 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2022 | 9,011 | 99,126 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2022 | 9,011 | 7,905,051 | - | - | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.65 per share. | 18 May 2022 | 3,510 | 7,901,541 | - | 9.7 | 33,872 | Common STock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.01 per share. | 09 May 2022 | 20,000 | 7,896,040 | - | 8.0 | 160,200 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.54 per share. | 07 Apr 2022 | 20,000 | 7,916,040 | - | 10.5 | 210,800 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.25 per share. | 04 Mar 2022 | 66,665 | 7,956,040 | - | 0.2 | 16,666 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2022 | 66,665 | 0 | - | - | Stock Option (Right to Buy) | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.58 per share. | 04 Mar 2022 | 18,800 | 7,937,240 | - | 12.6 | 236,504 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.79 per share. | 04 Mar 2022 | 1,200 | 7,936,040 | - | 13.8 | 16,548 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 163,158 | 163,158 | - | - | Stock Option (Right to Buy) | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 108,137 | 108,137 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.40 per share. | 07 Feb 2022 | 20,000 | 7,889,375 | - | 14.4 | 288,000 | Common Stock |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Feb 2022 | 5,000 | 7,842,710 | - | 0 | Common Stock | |
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | 22 Jul 2021 | 2,666,600 | 0 | - | - | Series A Preferred Stock | ||
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | 22 Jul 2021 | 2,666,600 | 2,666,600 | - | - | Common Stock | ||
| Cytek BioSciences Inc | Wenbin Jiang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2021 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges